| Literature DB >> 21138297 |
Makoto Hasegawa1, Tatsuhiro Miura, Kouji Kuzuya, Ayu Inoue, Se Won Ki, Sueharu Horinouchi, Tetsuo Yoshida, Tatsuki Kunoh, Koichi Koseki, Koshiki Mino, Ryuzo Sasaki, Minoru Yoshida, Tamio Mizukami.
Abstract
GEX1A is a microbial product with antitumor activity. HeLa cells cultured with GEX1A accumulated p27(Kip) and its C-terminally truncated form p27*. GEX1A inhibited the pre-mRNA splicing of p27, producing p27* from the unspliced mRNA containing the first intron. p27* lacked the site required for E3 ligase-mediated proteolysis of p27, leading to its accumulation in GEX1A-treated cells. The accumulated p27* was able to bind to and inhibit the cyclin E-Cdk2 complex that causes E3 ligase-mediated degradation of p27, which probably triggers the accumulation of p27. By using a series of photoaffinity-labeling derivatives of GEX1A, we found that GEX1A targeted SAP155 protein, a subunit of SF3b responsible for pre-mRNA splicing. The linker length between the GEX1A pharmacophore and the photoreactive group was critical for detection of the GEX1A-binding protein. GEX1A serves as a novel splicing inhibitor that specifically impairs the SF3b function by binding to SAP155.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21138297 DOI: 10.1021/cb100248e
Source DB: PubMed Journal: ACS Chem Biol ISSN: 1554-8929 Impact factor: 5.100